Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center), Kai He(The Ohio State University), Sophie Papa(Guy's Hospital), Emma L. Masteller(Integrated BioTherapeutics (United States)), Rana Fiaz(Integrated BioTherapeutics (United States)), Bernard Doger de Spéville(Hospital Universitario Fundación Jiménez Díaz), Viktoria Gontcharova(Integrated BioTherapeutics (United States)), Guang Chen(Integrated BioTherapeutics (United States)), Juan F. Rodríguez-Moreno(Hospital Universitario HM Sanchinarro), Sylvia M. Lee(University of Washington), Scott Gettinger(Yale Cancer Center), Melissa Catlett(Integrated BioTherapeutics (United States)), Friedrich Graf Finckenstein(Integrated BioTherapeutics (United States)), Rongsu Qi(Integrated BioTherapeutics (United States)), Simon Häfliger(University of Bern), Ammar Sukari(The Barbara Ann Karmanos Cancer Institute)
Cited by 108
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2015|1.2k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
|Journal of the National Comprehensive Cancer Network|2021|1k
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
|Journal of the National Comprehensive Cancer Network|2019|1k